Analysis of costs and results of the economic assessment of health interventions;Análisis de costes y resultados en la evaluación económica de las intervenciones sanitarias

Medicina Clinica

Volumn 122, Issue 11, 2004, Pages 423-429

  Prieto, Luis ^a   Sacristán, José Antonio ^a   Pinto, José Luis ^b   Badia, Xavier ^c   Antoñanzas, Fernando ^d   Del Llano, Juan ^e   Cobo, Erik ^f   García Alonso, Fernando ^f   Ortún, Vicente ^f   Rovira, Joan ^f   Rubio, Carlos ^f  

^a ELI LILLY AND COMPANY   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c Health Outcomes Research Europe   (Spain)

^d UNIVERSITY OF LA RIOJA   (Spain)

^e Fundacion Gaspar Casal   (Spain)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC ASPECT; HEALTH CARE COST;

EID: 2442535273     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13059544     Document Type: Article

References (47)

1. Eisenberg JM. Clinical economics: a guide to the economic analysis of clinical practices. JAMA 1989;262:2879-86.
2. Palmer S, Torgerson DJ. Definitions of efficiency. BMJ 1999;318:1136.
3. Robinson R. Economic evaluation and health care: the policy context? BMJ 1993;307:994-6.
4. Ortún-Rubio V, Pinto-Prades JL, Puis-Junoy J. El establecimiento de prioridades. Aten Primaria 2001;27:673-6.
5. Meltzer MI. Introduction to health economics for physicians. Lancet 2001;358:993-8.
6. Palmer S, Byford S, Raftery J. Types of economic evaluation. BMJ 1999;318:1349.
7. Robinson R. Economic evaluation and health care: what does it mean? BMJ 1993;307:670-3.
8. Ortún-Rubio V, Pinto-Prades JL, Puig-Junoy J. La economía de la salud y su aplicación a la evaluación. Aten Primaria 2001;27:62-4.
9. rd ed. New Jersey: Prentice Hall, 2000.
10. nd ed. Oxford: Oxford University Press, 1997.
11. Torgerson D, Raftery J. Measuring outcomes in economic evaluations. BMJ 1999;318:1413.
12. Johanesson, Jönsson B, Karlsson G. Outcome measurement in economic evaluation. Health Economics 1996;5:279-96.
13. Dolan P. Output measures and valuation in health. En: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press, 2001; p. 46-67.
14. Brouwer W, Rutten F, Koopmanschap M. Costing in economic evaluations. En: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press, 2001; p. 68-93.
15. Johnston K, Buxton MJ, Jones DR, Fitzpatrick R. Assessing the costs of healthcare technologies in clinical trials. Health Technol Assess 1999;3:1-76.
16. Grover SA, Ho V, Lavoie F, Coupal L, Zowall H, Pilote L. The importance of indirect costs in primary cardiovascular disease prevention. Arch Intern Med 2003;163:333-9.
17. Raftery J, Palmer S. Opportunity Cost. BMJ 1999;318:1551-2.
18. Koopmanschap MA, Rutten FF. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996;10;460-6.
19. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998;13:1-7.
20. Jacobs P, Fassbender K. The measurement of indirect costs in the health economics evaluation literature: a review. Int J Technol Assess Health Care 1998;14:799-808.
21. National Institute for Clinical Excellence (NICE). Health technology assessment: Guidance for manufacturers and sponsors. London: NICE, 2001.
22. nd ed. Otawa: Canadian Coordinating Office for Health Technology Assessment, 1997.
23. Mauskopf J, Schulman K, Bell L, Glick L. A strategy for collecting pharmacoeconomic data during phase II/III clinical trials. Pharmacoeconomics 1996;9:264-77.
24. Glick H, Polsky D, Schulman K. Trial-based economic evaluations: an overview and design and analysis. En: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford; Oxford University Press, 2001; p. 113-40.
25. Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Economics 1997;6:217-27.
26. Kuntz K, Weinstein M. Modelling in economic evaluation. En: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press, 2001; p. 141-71.
27. Drummond M, Pang F. Transferability of economic evaluation results. En: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press, 2001; p. 256-76.
28. Mason J. The generalisability of pharmacoeconomic studies. Pharmacoeconomics 1997;11:503-14.
29. Ostenbrink JB, Koopmanschap MA, Rutten FF. Standardization of costs: the Dutch manual for cost in economic evaluations. Pharmacoeconomics 2002;20:443-54.
30. Finkler SA. The distinction between cost and charges. Ann Intern Med. 1982;96:102-9.
31. Torgerson DJ, Raftery J. Discounting. BMJ 1999;319:914-5.
32. Cairns J. Discounting in economic evaluation. En: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press, 2001; p. 236-55.
33. Gravelle H, Smith D. Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Economics 2001;10:587-99.
34. Antoñanzas F, Rovira J, Juárez C. El problema de la actualización en la evaluación económica de proyectos sanitarios. Hacienda Pública 1999;148:3-25.
35. Robinson R. Economic evaluation and health care: cost and cost-minimisation analysis? BMJ 1993;307:726-8.
36. Puig-Junoy J, Pinto-Prades JL, Ortún-Rubio V. El análisis coste-beneficio en sanidad. Aten Primaria 2001;27:422-7.
37. Robinson R. Economic evaluation and health care: cost-benefit analysis? BMJ 1993;307:924-6.
38. Pinto-Prades JL, Ortún-Rubio V, Puig-Junoy J. El análisis coste-efectividad en sanidad. Aten Primaria 2001;27:275-8.
39. Robinson R. Economic evaluation and health care: cost-effectiveness analysis? BMJ 1993;307:793-5.
40. Schwartz JS. Necessity of using intermediate outcome to proxy long term effects: the example of thrombolytics. Pharmacoeconomics 1995;7:7-13.
41. Pinto-Prades JL, Puig-Junoy J, Ortún-Rubio V. Análisis coste-utilidad. Aten Primaria 2001;27:569-73.
42. Robinson R. Economic evaluation and health care: cost-utility analysis? BMJ 1993;307:859-62.
43. Mankiw NG. Principles of economics. Boston: Harcourt Brace & Co., 1998.
44. Badia Z, Roset M, Montserrat S, Herdman M, Segura A. La versión española del EuroQol: descripción y aplicaciones. Med Clin (Barc) 1999;112(Supl 1):79-85.
45. Prieto L, Sacristan JA. Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Ouctcomes 2003;1:80.
46. Sacristán JA, Ortún V, Rovira J, Prieto L, García-Alonso F. La evaluación económica en medicina. Med Clin (Barc). 2004;122:379-82.
47. Smith R. New BMJ policy on economic evaluations. BMJ 2002;325:1124.